These results suggest that HMGB1 contributes to the development of murine colitis by promoting the Th17 and Th1/Tc1 responses, and that EP can significantly inhibit HMGB1-Th17 and Thl/Tc1 pathway activation, which may provide better protection to mice with TNBS-induced colitis.
HMGB1 also mediates the development of murine colitis and colitis-associated cancer.
For example, a mixture of probiotic strains (VSL#3) ameliorates Th1-mediated murine colitis by inducing TGF-β-bearing Tregs and also suppresses diabetes development in NOD mice by inducing IL-10-producing cells in gut associated lymphoid tissues (GALT) [26], [28].
To test this hypothesis, we studied the effect of a newly developed, highly specific inhibitor of the A2B receptor, ATL-801, (N-[5- 1-cyclopropyl-2,6-dioxo-3-propyl-2,3,6,7-tetrahydro-1 H-puriN-[5- 1-cyclopropyl-2,6-dioxo-3-propyl-2,3,6,7-tetrahydro-1007) iN-[5- 1-cyclopropyl-2,6-dioxo-3-propyl-2,3,6,7-tetrahydro-1f muriN-[5- 1-cyclopropyl-2,6-dioxo-3-propyl-2,3,6,7-tetrahydro-1
In murine colitis models, IL-17A production from CD4+ T cells is protective because IL-17A directly suppresses the development of colitogenic Th1 cells via IL-17R expressed on activated CD4+ T cells (O'Connor et al. 2009).
This study was designed to investigate the effects of parthenolide on an experimental murine colitis model.
We induced murine colitis by intrarectal administration of 2, 4, 6-trinitrobenzene sulfonic acid (TNBS).
The three vaccines were evaluated in vivo in 2,4,6-trinitrobenzene sulphonic acid (TNBS -induced chronic murine coliTNBS -induced
We evaluated the contribution of colonic inflammation to osteopenia and its mechanism in a murine colitis model.
Treatment with a HIF-1α agonist boosts the innate immune response of the intestinal epithelium in a murine colitis model [72].
